INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to explore a new career... ByInvesting.com ...

One of the highlights of Eli Lilly's third-quarter results ... with fewer than 10% switching from Trulicity, said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus ...

The Q4 earnings call will be the first for Alphabet’s new chief financial officer, Anat Ashkenazi ... with the 22.5% weight loss seen with Eli Lilly’s (LLY) obesity treatment, Zepbound ...

Eli Lilly has called on financial regulators ... The issue was also alluded to by Lilly’s chief financial officer, Anat Ashkenazi, on the company’s fourth-quarter results call yesterday ...

Shares in the chipmaker were lower in pre-market trading, after closing Friday’s session with a 3% drop, following the launch ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...